Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 16/20 | 0.46 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16649443 | 1.00 | HTR2A (0.47) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL20438928 | 0.85 | KDM1A (0.51) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL12497812 | 0.85 | KDM1A (0.42) | KDM1AKDM1BKCNH2 | |
| SCHEMBL16649818 | 0.82 | KDM1A (0.69) | HTR2AKDM1AKDM1BKCNH2CHRNB2 | |
| SCHEMBL15286633 | 0.79 | KDM1A (0.69) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL247873 | 0.79 | KDM1A (0.69) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL2612405 | 0.79 | KDM1A (0.69) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL3609223 | 0.79 | KDM1A (0.69) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL15011508 | 0.79 | KDM1A (0.69) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL15011361 | 0.79 | KDM1A (0.69) | HTR2AHTR2CHTR2BKDM1AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2681215-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130338140-A1 | SERINE/THREONINE KINASE INHIBITORS | GENETECH, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2012118850-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338140-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K20 | HTR2A 4300/4885HTR2C 4639/4885HTR2B 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.